Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. 1983

W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth

The plasma distribution, disappearance half-time, MCR, and degradation of corticotropin-releasing factor (CRF) were studied in normal men who received a pulse injection of synthetic ovine CRF (oCRF). Graded iv doses of oCRF produced a linear increase in plasma immunoreactive oCRF (IR-oCRF). The calculated total plasma content of IR-oCRF 2 min after injection represented 41.7 +/- 2.5% (mean +/- SE) of the injected dose. The disappearance of IR-oCRF from plasma was characterized by a biexponential decay curve, with initial distribution and subsequent metabolic t 1/2 values of 6.1 +/- 0.5 and 55 +/- 3.8 min (mean +/- SE), respectively. In two subjects who were studied for 14-16 h after being given the largest dose of oCRF, there was third phase of disappearance, with a t 1/2 of 198 +/- 54 min. The MCR of IR-oCRF was 2.4 +/- 0.2 ml/min . kg (146 +/- 12 l/m2 . day) and was relatively constant over a 3000-fold dose range. The volume of distribution of IR-oCRF was 6.2 +/- 0.6 liters. The plasma IR-oCRF component, examined at increasing intervals after injection, was indistinguishable from the injected oCRF in that its apparent molecular size had not been altered, nor had its biological activity been attenuated. The continued circulation of apparently intact, biologically active oCRF for at least 90 min after injection was associated with sustained release of ACTH into the plasma. Thus, the clearance of oCRF from circulating human plasma is prolonged and appears to be responsible for the sustained release of ACTH that occurs after injection of this hormone-releasing factor.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
November 1982, The Journal of clinical endocrinology and metabolism,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
January 1979, The Journal of clinical endocrinology and metabolism,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
January 1984, Clinical endocrinology,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
June 1982, The Journal of clinical endocrinology and metabolism,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
December 1986, Endocrinologia japonica,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
May 1984, The Journal of clinical investigation,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
June 1985, The Journal of clinical investigation,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
January 1980, Materia medica Polona. Polish journal of medicine and pharmacy,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
March 1983, The Journal of clinical investigation,
W E Nicholson, and G S DeCherney, and R V Jackson, and C R DeBold, and H Uderman, and A N Alexander, and J Rivier, and W Vale, and D N Orth
January 1981, Acta endocrinologica,
Copied contents to your clipboard!